Monitoring of Breast Cancers Treated by Neoadjuvant Therapy Via Diffusion-weighted Magnetic Resonance Imaging

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 21, 2016

Primary Completion Date

January 1, 2019

Study Completion Date

January 31, 2019

Conditions
Breast Cancer
Interventions
DEVICE

Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)

MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.

Trial Locations (1)

1020

CHU Brugmann, Brussels

All Listed Sponsors
lead

Brugmann University Hospital

OTHER

NCT02798484 - Monitoring of Breast Cancers Treated by Neoadjuvant Therapy Via Diffusion-weighted Magnetic Resonance Imaging | Biotech Hunter | Biotech Hunter